Trial Profile

A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients With Early Alzheimer's Disease

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 May 2025 According to a ProMIS Neurosciences media release, company announced that first cohort completed in this PRECISE-AD trial.
25 Feb 2025 According to a ProMIS Neurosciences media release, Yaneicy Gonzalez-Rojas, M.D. and Ahmad Aswad, M.D., are the investigators in this trial.
25 Feb 2025 According to a ProMIS Neurosciences media release, dosing has been initiated in multiple patients in this trial. The 6-month interim results are expected in 1H 2026 and topline results are expected in 2H 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com